{"id":154444,"date":"2026-11-18T12:32:01","date_gmt":"2026-11-18T03:32:01","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4892-20261118-01_wp_product_announcement\/"},"modified":"2026-11-18T12:32:01","modified_gmt":"2026-11-18T03:32:01","slug":"4892-20261118-01_wp_product_announcement","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/","title":{"rendered":"Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis"},"content":{"rendered":"<p>In joint research with Keio University and Fujita Health University, a platform technology for a novel osteochondral regeneration therapy for idiopathic medial femoral condyle osteonecrosis was developed using a bio 3D printer. An investigator-initiated clinical trial to evaluate the safety and efficacy of the investigational product KCF-BC1 will commence. The trial will be conducted at Keio University Hospital. Impact on financial results is currently being evaluated.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4892","jir_company_name":"Cyfuse Biomedical K.K.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4892-20261118-01.pdf","jir_short_summary":"In joint research with Keio University and Fujita Health University, a platform technology for a novel osteochondral regeneration therapy for idiopathic medial femoral condyle osteonecrosis was developed using a bio 3D printer. An investigator-initiated clinical trial to evaluate the safety and efficacy of the investigational product KCF-BC1 will commence. The trial will be conducted at Keio University Hospital. Impact on financial results is currently being evaluated.","jir_summary":"### Overview of New Technology and Start of Clinical Trial\nIn joint research with the Department of Orthopaedic Surgery at Keio University School of Medicine and Fujita Health University, Cyfuse Biomedical K.K. developed an osteochondral plug (KCF-BC1) that simultaneously regenerates superficial cartilage and deep subchondral bone using adipose-derived mesenchymal stromal cells and bio 3D printer technology. The scaffold-free approach is expected to reduce the risk of foreign body reactions. An investigator-initiated clinical trial using this product will commence.\n\n### Future Plans and Social Significance\nThis technology aims for regulatory approval in Japan as a regenerative medicine product and will be advanced toward commercialization and international expansion through public-private-academic collaboration. In the long term, it may contribute to extending healthy life expectancy in an aging society by enabling biological regeneration and reducing reliance on implants.","jir_financial_highlights":"Revenue: Unknown (Unknown)\nImpact from start of clinical trial: Unknown (Unknown)","jir_category":"","jir_hashtags":"#CyfuseBiomedical, #ProductAndClinicalTrial, #RegenerativeMedicine","jir_key_figures":"Investigational product name: KCF-BC1 (osteochondral plug)\nIndication: Idiopathic medial femoral condyle osteonecrosis\nPlanned start of clinical trial: To begin at Keio University Hospital","jir_meta_title":"Cyfuse Biomedical K.K. \u2014 Investigator-Initiated Clinical Trial for New Osteochondral Regeneration Therapy Begins\uff5cNovember 2026","jir_meta_description":"Cyfuse Biomedical K.K., in joint research with Keio University and Fujita Health University, developed a bio 3D-printed platform technology for osteochondral regeneration. An investigator-initiated clinical trial to evaluate the safety and efficacy of KCF-BC1 has commenced. Future development and impact on financial results are undetermined.","jir_og_title":"Cyfuse Biomedical K.K. \u2014 Investigator-Initiated Clinical Trial for New Osteochondral Regeneration Therapy Begins\uff5cNovember 2026","jir_og_description":"Cyfuse Biomedical K.K. announced the development of a foundational technology for a new osteochondral regeneration therapy and the start of a clinical trial. KCF-BC1 will have its safety and efficacy evaluated at Keio University Hospital. Watch for future business developments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-154444","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/\",\"name\":\"Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-18T03:32:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/","url":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/","name":"Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-18T03:32:01+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261118-01_wp_product_announcement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice of Start of Investigator-Initiated Clinical Trial Based on Joint Research with Keio University and Fujita Health University \u2014 Development of a Novel Osteochondral Regeneration Platform Technology for Idiopathic Medial Femoral Condyle Osteonecrosis"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59821","title":"CYFUSE BIOMEDICAL K K","ticker":"4892"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154444"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154444\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154444"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154444"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}